Votrient (pazopanib) is a drug-agent of GlaxoSmithKline that appears to work through targeting angiogenesis and growth pathways, and has been approved for use in renal cell carcinoma and advanced soft tissue sarcoma, and now is under study for use in neuroendocrine tumors. Two other recent targeted agents that have been approved by the U.S. FDA for the treatment of neuroendocrine tumors are everolimus and sunitinib.
Park and colleagues at Gachon University in Korea have recently published the results of a Phase II clinical trial using pazopanib as a single agent in the treatment of gastrointestinal and pancreatic neuroendocrine tumors in the British Journal of Cancer.
The authors treated 37 patients with metastatic neuroendocrine tumors with pazopanib in 2010 to 2012. The patients in the study showed an objective response rate of 18.9%. An independent review demonstrated a higher overall response rate of 24.3%, with nine confirmed partial responses.
The authors suggest that this effect appears to be similar to that of other recent targeted therapies, which provides impetus for further study of this potential agent for consideration in the area of neuroendocrine tumors.
Dale O’Brien, MD